NEURONETICS INC (STIM) Stock Price, Forecast & Analysis
USA - NASDAQ:STIM - US64131A1051 - Common Stock
STIM Key Statistics, Chart & Performance
The current stock price of STIM is 1.595 USD. In the past month the price decreased by -26.02%. In the past year, price increased by 180.28%.
STIM Latest News, Press Relases and Analysis
STIM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.33 | 228.64B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.98B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.68 | 151.60B | ||
| SYK | STRYKER CORP | 27.19 | 136.91B | ||
| BDX | BECTON DICKINSON AND CO | 13.44 | 55.56B | ||
| IDXX | IDEXX LABORATORIES INC | 53.23 | 53.70B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.41 | 50.41B | ||
| RMD | RESMED INC | 24.81 | 35.85B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.6 | 32.69B | ||
| PODD | INSULET CORP | 72.49 | 23.32B | ||
| DXCM | DEXCOM INC | 31.46 | 22.95B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.97 | 17.58B |
Related stock screener links
About STIM
Company Profile
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Company Info
NEURONETICS INC
3222 Phoenixville Pike
Malvern PENNSYLVANIA 19355 US
CEO: Keith J. Sullivan
Employees: 716
Phone: 18776007555
NEURONETICS INC / STIM FAQ
What does NEURONETICS INC do?
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 716 full-time employees. The company went IPO on 2018-06-28. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The firm provides more than 7.1 million treatments to over 1,95,000 patients.
Can you provide the latest stock price for NEURONETICS INC?
The current stock price of STIM is 1.595 USD. The price decreased by -19.85% in the last trading session.
What is the dividend status of NEURONETICS INC?
STIM does not pay a dividend.
What is the ChartMill rating of NEURONETICS INC stock?
STIM has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of NEURONETICS INC (STIM) based on its PE ratio?
NEURONETICS INC (STIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.82).
Should I buy STIM stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on STIM.
What is the expected growth for STIM stock?
The Revenue of NEURONETICS INC (STIM) is expected to grow by 109.15% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
STIM Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to STIM. When comparing the yearly performance of all stocks, STIM is one of the better performing stocks in the market, outperforming 95.18% of all stocks.
STIM Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to STIM. Both the profitability and financial health of STIM have multiple concerns.
STIM Financial Highlights
Over the last trailing twelve months STIM reported a non-GAAP Earnings per Share(EPS) of -0.82. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -36.24% | ||
| ROE | -179.75% | ||
| Debt/Equity | 2.05 |
STIM Forecast & Estimates
9 analysts have analysed STIM and the average price target is 6.63 USD. This implies a price increase of 315.67% is expected in the next year compared to the current price of 1.595.
For the next year, analysts expect an EPS growth of 57.31% and a revenue growth 109.15% for STIM